Abstract 338P
Background
Cancer development is aggravated by a rare population of cells, termed cancer stem cells (CSCs), that uniquely initiates and sustains the disease. Although CSCs can orchestrate the immune systems in favour of tumor, the detailed mechanisms underlying their immunomodulatory effects remain elusive. Recent reports indicate the contribution of exosomes, secreted from various cells, as mediators of cell-to-cell communication and also as a mediator of immune modulation in the tumor microenvironment.
Methods
Breast CSCs (bCSCs) were purified from breast cancer cell lines and human breast tumor tissues following which CSC-derived exosomes (CDEs) were isolated. Peripheral blood mononuclear cells were isolated from the blood of healthy donors and breast cancer patients, co-cultured with CDEs, and T regulatory (Treg) cell generation was evaluated.
Results
We found that bCSCs are able to generate CD4+CD25+FOXP3+ Treg cells having suppressive activity. Our search for the underlying mechanism revealed for the first time that bCSC-secreted exosomes contain FOXP3 protein that uniquely initiates acquisition of Treg characteristics in the infiltrating T lymphocytes. Exosomes from FOXP3-ablated bCSCs failed to augment Treg cell generation indicating the requirement of bCSC-gifted FOXP3 in Treg generation. Interestingly, perturbation of transcription or translation in T naïve cells significantly decreased CDE-augmented FOXP3 level signifying that CDE-FOXP3 utilizes the transcription and translational machineries of T naïve cells to induce Treg cell generation. In fact, exosome-shuttled FOXP3 binds to the CNS2 region of the Foxp3 promoter in T lymphocytes, thus resulting in a sustained expression of FOXP3 and further leading to induction of other genes of Foxp3 interactome, thereby phenotypically converting the T cells to Treg cells.
Conclusions
Collectively our data demonstrates that bCSC-shed exosomal FOXP3 plays an important role in procreation of Treg cells within the tumor microenvironment thus leading to tumor-induced immune suppression. Breaching the deadly-liaison between them might be a promising strategy for breast cancer therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prof. Tanya Das, Professor, Division of Molecular Medicine, Bose Institute.
Funding
Department of Science and Technology, Govt. of Inda Council of Scientific & Industrial Research (CSIR), Govt. of India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract